

October 30, 2008

Dissolution of the European Subsidiary Fujisawa Ireland Ltd.

Astellas Pharma Inc. (“Astellas”; President and CEO: Masafumi Nogimori) announced today that it has decided to dissolve its European subsidiary, Fujisawa Ireland Ltd. (headquarters: Kerry, Ireland).

1. **Reasons for the dissolution**
Astellas was created as a result of the merger of the former Yamanouchi Pharmaceutical Co., Ltd. and the former Fujisawa Pharmaceutical Co., Ltd. on April 1, 2005. Astellas has decided to dissolve Fujisawa Ireland Ltd. because the transfer of its functions to Astellas Ireland Co., Ltd., which was established in October 2005 as Astellas’s production subsidiary in Europe, has been completed.
2. **Outline of the subsidiary to be dissolved**

(As of March 31, 2008)

1) Company name	Fujisawa Ireland Ltd.
2) Business	Manufacturing and marketing of pharmaceuticals
3) Date of establishment	September 1990
4) Location	Killorglin, Co Kerry, Ireland
5) Representative	Mitsuhiro Matsuda
6) Capital	*€1,172,093
7) Total shares outstanding	*1,710,000 shares
8) Shareholders' equity	*€223,107
9) Total assets	*€223,107
10) Fiscal year end	March 31
11) Number of employee	1
12) Major customers and suppliers	Astellas Pharma Inc.
13) Major shareholders (%)	Astellas B.V. (100%)

*Figures as of July 31, 2008

3. **Financial impacts of the dissolution**
The dissolution will have no impact on Astellas’s business performance.
4. **Schedule for dissolution**
The winding-up has been resolved at the extraordinary general meeting of Fujisawa Ireland Ltd. on September 29, 2008 (local time).
*The date of dissolution has not yet been decided.

#####

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 http://www.astellas.com